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Purpose: Concurrent chemoradiation is standard-of-care for patients with squamous 
cell carcinoma of the anus (SCCA). Poor compliance to chemotherapy, radiotherapy 
treatment interruptions and unplanned breaks may impact adversely on long-term 
outcomes.  
 
Methods: The ACT II trial recruited 940 patients with localized SCCA, and assigned 
patients to mitomycin (week 1) or cisplatin (weeks 1 and 5), with fluorouracil (weeks 1 
& 5) and radiotherapy (50·4 Gy in 28 fractions over 38 days). This post-hoc analysis 
examined the association between baseline factors (age, gender, site, T-stage and N-
stage), and compliance to treatment (radiotherapy and chemotherapy), and their 
effects on loco-regional failure-free survival (LRFFS), progression-free survival (PFS) 
and overall survival (OS).  
 
Compliance was categorized into groups. Radiotherapy: 6 groups according to total 
dose (TD) and overall treatment time (OTT): Chemotherapy 3 groups: (A = per-
protocol; B = dose reduction or delay; C = omitted).  
 
Results: 931/940 patients were evaluable for radiotherapy and 936 for chemotherapy 
compliance. Baseline Glomerular filtration rate (GR) <60 mL/min and cisplatin were 
significantly associated with poor week 5 compliance to chemotherapy (p 0.003 and 
0.02, respectively). Omission of week 5 chemotherapy was associated with 
significantly worse LRFFS (HR 2.53 [1.33 to 4.82] p=0.005). Dose reductions/delays 
or omission of week 5 chemotherapy were associated with significantly worse FPFS 
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(HR: 1.56 [95%CI: 1.18-2.06], p=0.002 and HR: 2.39 [95%CI: 1.44-3.98}, p=0.001, 
respectively) and OS (HR: 1.92 [95%CI: 1.41-2.63], p<0.001 and (HR: 2.88 [95%CI: 
1.63-5.08], p<0.001, respectively). Receiving the target radiotherapy dose in >42 days 
is associated with worse PFS and OS (HR:1.72 (95%CI:1.17-2.54), p=0.006).  
 
Conclusion:  Poor compliance to chemotherapy and radiotherapy were associated 
with worse LRFFS, PFS and OS. Treatment interruptions should be minimized, and 















Standard treatment for localized squamous cell carcinoma of the anus (SCCA) is 
chemoradiation using concurrent fluorouracil and mitomycin C1,2 This combination has 
been tested in randomized trials3,4,5,6,7 and results in good outcomes for cT1/T2 
cancers7, but less so for cT3/T4 cancers7,8. Loco-regional failure is the predominant 
pattern of relapse7,9, potentially influenced by innate chemo/radio-resistance, sub-
therapeutic radiotherapy total dose (TD) delivered and poor chemotherapy 
compliance. 
 
Early phase III trials in SCCA planned breaks in treatment of 6-8 weeks to manage 
acute treatment-related toxicities3,4, Evidence for the importance of overall treatment 
time (OTT) exists in squamous carcinomas of the head and neck (SCCHN)10,11. 
Evidence in SCCA is inconsistent, but strict adherence to protocol achieved 
significantly better overall survival (OS)12 and suboptimal compliance to the planned 
radiotherapy TD adversely impacted on local control and OS13. More recent trials, 
without planned radiotherapy interruptions, reported high levels of acute toxicity to 
both modalities6,7, leading to poor compliance in some patients. With the increasing 
use of intensity modulated radiotherapy (IMRT), toxicity is reduced allowing a potential 
reduction in average OTT14. 
 
Since chemotherapy and radiotherapy independently enhances the other, compliance 
for each is required for optimum results. In the second United Kingdom Anal Cancer 
Trial (ACT II) the intention was to deliver a standard central axis tumour dose 
(irrespective of stage) of 50.4Gy in 28 fractions in 38 days. Other contemporary trials 
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used an initial dose of 45Gy, but were permissive, according to stage and response, 
as regards TD and number of fractions6,15.   
 
Compliance refers to conformity to trial recommendations with respect to timing, dose, 
and frequency of the intended radiotherapy or chemotherapy treatment. We could find 
no standard definition for radiotherapy compliance (TD or OTT) within chemoradiation 
schedules in SCCA, although the UK contemporary national guidance in 2015 
recommended a maximum of 4 days extension to the OTT16. In contrast, the RTOG 
9811 trial allowed treatment breaks up to 10 days6. Thus ACT II, is uniquely placed to 
reliably assess the impact of compliance in terms of TD, OTT and chemotherapy on 
cancer outcomes. The permissive design of the other randomised trials precludes 
such an analysis. 
 
The present analysis aimed to quantify compliance to radiotherapy (TD and OTT) and 
week 5 chemotherapy. We aimed to identify independent factors to predict better or 
worse compliance, and to investigate the impact on oncological outcomes i.e. loco-
regional failure-free survival (LRFFS), progression-free survival (PFS) and OS). This 
is a relevant research question, which cannot be answered by only looking at those 





Materials and Methods 
Trial design and participants 
ACT II was a randomized factorial phase III trial with 940 patients enrolled between 
2001-2008, which investigated whether replacing mitomycin with cisplatin in the 
chemoradiation schedule improves complete response rate, and the impact of 
maintenance chemotherapy (fluorouracil/cisplatin) after chemoradiation. Methods and 
results have previously been reported7.  
Protocol Guidance and modifications for toxicity  
Radiotherapy: All patients were to receive radiotherapy (50.4Gy in 28 daily fractions 
over 38 days), in two-phases to the International Commission on Radiation Units and 
Measurements (ICRU) intersection point. A Monday start for radiotherapy was 
recommended, but not mandated.  As such, planned OTT for those commencing 
treatment Monday to Wednesday or Thursday to Friday would be 38 and 40 days 
respectively. Protocol interruptions to radiotherapy were only recommended for 
haematological and gastrointestinal NCI Common Toxicity Criteria (CTC) grade 3 and 
4. The protocol did not encourage, but allowed clinician’s discretion to interrupt 
radiotherapy for moist skin desquamation, gastrointestinal and haematological toxicity. 
There was no guidance in the protocol about how, or when, to compensate for such 
interruptions. 
Chemotherapy: Patients received fluorouracil 1000 mg/m² per day on days 1–4 (week 
1) and 29–32 (week 5) by continuous intravenous infusion with radiotherapy, and 
either, 12 mg/m² of mitomycin as an intravenous bolus on day 1 only (maximum single 
dose 20 mg), or 60 mg/m² of cisplatin by intravenous infusion on days 1 and 29 
(maximum single dose of 120 mg).  
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Patients with a calculated GFR of 50-60 ml/min were eligible only if the subsequently 
tested GFR was ≥ 50ml/min. Cisplatin and MMC dose reductions were prescribed for 
patients with a GFR of 50–59 mL/.    
Fluorouracil doses were reduced for week 5 chemotherapy in severe toxicity following 
week 1. Specifically, 25% and 50% dose reductions were recommended for grade 3 
and 4 haematological toxicity respectively. Omission of fluorouracil was mandated in 
the case of G4 diarrhoea. Week 5 cisplatin was omitted if the GFR fell below 50ml/min. 
Radiotherapy interruptions for toxicity delayed chemotherapy, so that the two 
modalities were given together.  
Treatment compliance definition 
Per-protocol radiotherapy compliance was defined prior to analysis as completion of 
protocol radiotherapy 50.4 Gy in 28 fractions within an OTT of 38-42 days (including 
up to 4 days for logistical problems and public holidays) i.e. 10% extension.  Poor 
radiotherapy compliance was therefore defined as extending >42 days. Table 1 shows 
how we categorized radiotherapy and week 5 chemotherapy compliance.  
Statistical analysis 
Categorical variables were summarized in terms of frequency and percentage, and 
continuous variables in terms of median and range.  
The association between baseline factors and radiotherapy TD delivered was 
examined using Kruskall Wallis test. The OTT by groups 1-6 was evaluated using cox 
regression. Logistic regression assessed any association between baseline 
characteristics and the risk of radiotherapy interruptions due to toxicity and odds ratios 
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(OR), 95% CI and p-values are reported. Fisher’s exact test examined whether any 
baseline characteristics were associated with chemotherapy compliance.  
Kaplan-Meier plots and cox regression assessed the effect of 
radiotherapy/chemotherapy compliance (groups 1-6 and A-C) on PFS and OS with 
subgroup analysis by T-stage. To account for potential immortality bias, the time to 
event outcomes were measured as time from 7 weeks post registration until the event 
of interest, or date of last follow-up for censored patients. Hazard ratios (HR), 95%CI 




Of 940 patients, 931 were evaluable for radiotherapy and 936 for chemotherapy 
compliance respectively [Figure 1]. Median follow-up was 5.1 years (95%CI: 5.0-5.3). 
Table 2, shows baseline characteristics were similar amongst all patients, and 
amongst groups 1-6 and groups A-C, except week 5 chemotherapy delays and 
reductions were more common in the cisplatin arm and amongst patients with GFR≥60 
mL/min. 
 
Previously reported compliance details7 have been updated. [Table 3]. The median 
radiotherapy TD was 50·4 Gy (range 5.6Gy – 56.7Gy, IQR 50·4–50·4) in a median of 
28 fractions (range 3-32). Median OTT for radiotherapy was 38 days (range 3-81 days, 
IQR 38–39). 98/931 (11%) patients had at least one day’s interruption in radiotherapy 
documented due to toxicity, but the precise cause was not specified in 82/98 patients 
(84%). A further 40/931 (4%) had interruptions due to non-toxicity (19 administrative 
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i.e. machine breakdown, transport) 11 patient choice (weather, illness) and in 10 the 
reason was not specified. Only 18 patients had treatment interruptions of >8 days.  For 
the 15 patients in Group 6, the extension to OTT ranged from1-29 days with a median 
of 7 days. Radiotherapy was completed as per-protocol in 379/467 (81%) in the 
mitomycin arm and 377/464 (81%) in the cisplatin arm respectively. There was no 
evidence of an association between baseline factors, type of chemotherapy 
(mitomycin, cisplatin), age, gender, clinical T or N stage, GFR, WBC and radiotherapy 
compliance [Table A1 & A2].  
 
 
Adjusting for interruptions due to toxicity, we observed a statistically significant effect 
of radiotherapy OTT on PFS and OS - if patients receive less than the planned target 
dose or if the planned target dose is extended >42 days [Figure 2 and Online Table 
A3, Figure A1, Figure A2]. Patients who received the planned radiotherapy dose 
within 38-42 days had better outcomes. If OTT was extended >42 days, there was a 
significant increase in the risk of PFS event and death (PFS, HR: 1.58 (95%CI: 1.12 




Week 1 chemotherapy was delivered without reductions/delays to 99% of patients in 
both mitomycin (433/465) and cisplatin arms (429/464).  Chemotherapy delays or per-





Data on week 5 chemotherapy was available for 936 patients. No chemotherapy was 
administered to 35/936 (3.7%), and 14% (68/471) in the mitomycin and 21% (96/465) 
in the cisplatin arm had delays or reductions. Completion of week 5 chemotherapy 
per-protocol was higher in the mitomycin arm 388/471 (82%) compared to the cisplatin 
arm 349/465 (75%). Poor compliance reflected acute toxicity, mainly haematological 
toxicity, worsening renal function, mucositis, diarrhoea and severe asthenia.  
 
There was no association between baseline factors and week 5 chemotherapy 
compliance, except for baseline GFR in mL/min (p=0.003) (Table A2). Patients with 
baseline GFR of ≥60mL/min were more likely to receive week 5 per-protocol 
chemotherapy, 711/891 (80%) compared with <60mL/min - 26/45 (58%).  
The week 5 chemotherapy 5FU intensity is comparable in both the mitomycin and 
cisplatin arms. 
 
Dose reductions/delays or omission of week 5 chemotherapy were associated with 
worse LRFFS (HR:1.35 [0.92 to 1.98] p=0.13 and HR 2.53 [1.33 to 4.82] p=0.005 
respectively). There was a statistically significant association between receiving per-
protocol week 5 chemotherapy and PFS (p=0.0006) and OS (p<0.0001) [Figure 3, 
Table A4]. Omission of chemotherapy during chemoradiation was associated with >2-
fold increase in the risk of a PFS event (HR: 2.39 (95%CI: 1.44 to 3.98), p=0.001) 
compared with patients who completed week 5 per-protocol and an increased risk of 
death (HR 2.88 (95%CI: 1.63 to 5.08), p<0.001). Patients who received week 5 
chemotherapy with delays/reductions compared with per-protocol, also had a 
significant increased risk of a PFS event (HR: 1.56 (95%CI: 1.18 to 2.06), p=0.002) 




There is evidence of an interaction between chemotherapy week 5 compliance and T-
stage for PFS (p=0.04) and OS (p=0.04) (Table A4 and Fig 3). The findings suggest 
patients with more advanced T-stage (T3-4) who failed to receive per-protocol week 5 
chemotherapy have a worse PFS (p<0001) and an increased risk of death (p<0001) 
compared with per-protocol treatment (Table A5).  
 
Compliance varied within the 52 participating sites, particularly in the 16 (31%) which 
recruited <10 patients (Figure A3). The impact of facility volumes and academic 
centres on outcomes has been highlighted in SCCHN 17. In ACT II, these 16 hospitals 
treated 79 patients; 30 of whom (38%) did not complete per-protocol treatment, 
compared with 36 sites entering ≥10 patients where only 145/852 (17%) did not 
complete per-protocol treatment. Amongst sites recruiting ≥10 patients, the correlation 
between the number of patients recruited in each site and the percentage of patients 
who received radiotherapy as per-protocol was weak and not statistically significant 
(Spearman correlation coefficient=-0.20, p value = 0.24). 
 
Discussion 
ACT II mandated a TD (irrespective of stage) of 50.4Gy in 28 fractions in 38 days. This 
retrospective post-hoc analysis quantifies compliance of patients treated with 
chemoradiation in the trial. We demonstrated that extending OTT of radiation by >42 
days, and the omission of week 5 chemotherapy or reduced doses/delays are 
associated with inferior PFS and OS. This represents important information for 




Since the protocol mandates chemotherapy and radiation are delivered concomitantly, 
40% of patients who had a delay of radiotherapy OTT >42 days, also had the week 5 
chemotherapy delayed and/or dose reduced, but only 4% had no chemotherapy at all. 
The association between better chemotherapy week 5 compliance in the patients who 
had RT as per protocol compared with patients who had RT prolonged with OTT >42 
days (40.4% vs 13.76% [p<0.001] respectively implies that the inability to deliver the 
radiotherapy in a timely fashion is the main driver of the poor outcomes. 
 
A retrospective pooled analysis of the RTOG 87-04 and RTOG 98-11 trials (Ben Josef 
2010) concluded that total treatment time, but not duration of radiation therapy, has a 
detrimental effect on local failure and colostomy rate in anal cancer. However, a third 
received NACT and 62% of patients in RTOG 9811 required a treatment break 
resulting in an overall median OTT of 49 days and 302/644 (47%) patients received a 
total dose of only 45Gy. For these reasons, the data cannot be compared with our 
data in ACT II, which gave no NACT, used a mandated dose of 50.4Gy, and treatment 
breaks for skin toxicity were not permitted. 
 
The strength of the study is that the data was collected prospectively within the ACT 
II trial with a large number of patients in study arms with equal distribution of age, 
gender, clinical stage of disease, ECOG performance status, and localization of 
primary tumour (canal /margin). TD, the fraction size of radiation and hence biological 
equivalent dose (BED) and the chemotherapy protocols were highly homogeneous. In 
particular the consistency of the OTT [median 38 days (IQR 38-39 days)] in both 
mitomycin and cisplatin groups strengthens our conclusions. Outcomes are also 




Quality assurance (QA) in radiotherapy has previously focussed on target delineation, 
dosimetry, PTV coverage or dose‐volume parameters, OTT has been less rigorously 
assessed. Compliance has been categorized as acceptable, unacceptable and other 
(no radiotherapy or incomplete radiotherapy due to death, progression or refusal)18. 
Some trials consider a tolerance of +/- 10% as per-protocol with >10% an 
unacceptable deviation19. In ACT II, the QA protocol did not specify how many days 
extension to OTT would classify minor or major deviations.  
 
The limitations of this study include the fact that this was an unplanned ‘post hoc’ 
retrospective analysis. The groups were retrospectively defined (based on 
contemporary UK recommendations and +/- 10% deviations), but the definitions were 
set prior to any analysis of data. Since patients are not randomized into these groups, 
sources of bias cannot be controlled for. Few patients failed to achieve per-protocol 
compliance and hence these represent small subgroup analyses. 
 
Larger field sizes could have contributed to toxicity and compliance, but without 
reviewing individual field sizes in the light of staging CT and MRI scans to assess their 
fidelity, we are unable to provide detailed data. However, it is reassuring that median 
radiotherapy TD delivered, OTT for radiotherapy and risk of radiotherapy interruptions 
due to toxicity are similar between T1, T2, T3 and T4 tumours, and there is no evidence 
of a statistical difference (p= 0.68, p=0.47 and p=0.88 respectively). Table A1.  
Reductions/delays in week 5 chemotherapy was observed in 15% for T1/T2 and 19% 




A further limitation is that we were unable to test for imbalances between the groups 
in human papilloma virus–associated cancer (p16+), smoking history or tumour 
infiltrating lymphocytes as this data was not collected and we were unable to adjust 
for co-morbidity. 
 
The association between compliance groups and outcomes can reflect an outcome-
by-outcome analysis, which is prone to bias as patients who complete per-protocol 
treatment tend to be younger, fitter, more robust, without co-morbidity and hence have 
a better prognosis. Any association between compliance and outcome does not 
therefore necessarily mean that the actual treatment received is associated with 
better/worse outcomes, although if other reasons such as poor adherence without 
toxicity and administrative issues can be shown to be responsible, then more robust 
associations can be drawn.  Our results show no difference in the proportion of patients 
with an OTT >42 days for patients > 65 years compared to younger patients. 
 
There are a number of potential strategies to improve compliance. Prospective data 
from the RTOG 0529 trial suggest IMRT reduces acute toxicity. Significant reductions 
were reported in grade 2+ hematologic (73% vs. 85%; P= .032), grade 3+ 
gastrointestinal (21% vs. 36%; P = 0.008), and grade 3+ dermatologic events (23% 
vs. 49%; P<0.0001)14.  Subsequent analyses suggested acute AEs correlated with 
radiation dose to the small bowel and anterior pelvic contents20 in keeping with the 
finding of improved toxicity using IMRT. This is similar to a UK audit of SCCA, where 
reduced toxicity resulted in radiotherapy interruptions falling from 8%-4% with IMRT 




Despite the use of IMRT, compliance remains an issue since treatment breaks in the 
51 assessable patients in the RTOG 0529 trial were required by 49%, compared with 
62% in RTOG 9811 (P=0.09), Median OTT with IMRT was 43 days with TD 54Gy, 
compared with 49 days and TD 50.4Gy in the standard fluorouracil/mitomycin arm of 
RTOG 9811l (P<0.0001)14.  Additionally, 8/51 (16%) patients did not complete per-
protocol chemotherapy. A recent retrospective pooled analysis of patients treated with 
IMRT in the UK reported failure to complete treatment or interruptions (defined as any 
extension >2 days over the planned OTT) as 5.2%. In multivariate analysis a HR of 
5.80 (1.96-17.29) was found in this group for persistent disease (p=0.001) compared 
with treatment delivered per-protocol22. Therefore, despite IMRT, poor compliance 
remains an issue.   
 
A retrospective analysis, using the National Cancer Data Base (NCDB), compared 
outcomes of patients with SCCA treated with IMRT or 3D-CRT23. They reported 
improved OS for those treated with shorter treatment times (P < .0001) and at high-
volume centers [>18 cases per-year] (P = .0011). A more recent NCDB analysis of 
CRT (2004–2014), also showed prolonging RT was independently associated with 
reduced OS - with most effect when RT was delayed >2 days24.  
 
 
Additional proactive strategies could further improve compliance. First, meticulous 
hydration in the first cycle of chemotherapy might minimize toxicity in patients with 
baseline GFR<60. Second, the association between absolute nadir and the V10/V20 
of pelvic and lumbosacral bone marrow could be addressed by bone marrow sparing, 




Data on chemotherapy compliance in SCCA is sparse (Table A6). In the ACCORD 03 
trial 78/82 (95%) (Arm C) and 71/75 (95%) (Arm D) received the second cycle of 
concurrent chemotherapy in the 157 patients, who received chemoradiation without 
induction chemotherapy15. However, this second cycle was adjusted (50-75%) 
according to early toxicity.  
 
In ACT II prolonged OTT in radiotherapy and poor compliance to week 5 
chemotherapy were associated with worse PFS and OS outcomes. The large 
randomised trial dataset with standardised radiotherapy fields and the same mandated 
total dose, protocol-defined chemotherapy and toxicity prospectively captured, 
increases the likelihood that our findings are applicable to routine clinical practice, and 
should have a significant impact on the delivery of treatment regimens. 
 
Although a ‘post hoc’ analysis is not powered for comparisons, the data can assist the 
design of future trials. We believe that there is an unmet need for studies to identify 
factors associated with compliance, and whether compliance could be used as a 
`marker’ predictive of the outcome. In this study, prolongation of OTT was not 
associated with any clinical factors, but initial GFR impacted on the ability to deliver 
week 5 chemotherapy in full.  
 
This analysis strongly suggests radiotherapy should be delivered per-protocol in a 
timely manner in high volume facilities, avoiding interruptions, to achieve optimal 
treatment outcomes. Better outcomes are observed when week 5 chemotherapy is 
administered in full without dose reduction or delay. Patients with poor compliance 
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may require closer monitoring following chemoradiation to identify local recurrence at 
an early stage.  
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